An injectable type of hormone used to treat many children has been associated with a rise in intraocular pressure (IOP) in a new study carried out by experts based in Israel.
In a report published in this month's Pediatrics Journal, researchers at Tel Aviv University revealed how they monitored the IOP of 55 children who had been receiving recombinant human growth hormone (rhGH) treatment for an average of 31 months on average.
These patients were compared with 24 children with similar conditions who had not been treated in the same way and the experts found that the rate of IOP was much greater in those who had undergone hormone treatment than those who did not.
"IOP in children treated with rhGH is increased compared with a similar population without treatment and compared with healthy population normograms," the expert wrote.
Based on this, they concluded that IOP is associated with longer treatment duration and higher dosages.